Universal BCMA-CD19 CART

Phase 1Cell therapy

Universal BCMA-CD19 CART is one of 48 small molecule programs targeting Safety and Efficacy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyNot yet recruiting

Safety and EfficacyPhase 1

Not yet recruiting

Competition

Competitive Landscape

131 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

3 2

Actemra

Roche

Phase 3

1 3

Humira

RRanbaxy Laboratories Limited

Phase 3

3 4

Rayos

RRoxane Laboratories

Phase 3

3 5

Empaveli

Apellis Pharmaceuticals

Phase 3

2 6

CAB LA

GSK

Phase 3

1 7

Cytosar

Teva

Phase 2

3 8

Tagrisso

AstraZeneca

Phase 2

3 9

B/F/TAF

Gilead

Phase 3

5 10

Selzentry

GSK

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Not yet recruiting·BBioray Laboratories·Phase 1·NCT06633042·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Universal BCMA-CD19 CART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Universal BCMA-CD19 CART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Universal BCMA-CD19 CART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioray Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: BBioray Laboratories

Universal BCMA-CD19 CART

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News